Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Rebastinib - Deciphera Pharmaceuticals

Drug Profile

Rebastinib - Deciphera Pharmaceuticals

Alternative Names: DCC-2036; DP-1919; DP-1919.TO

Latest Information Update: 29 Jan 2024

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Deciphera Pharmaceuticals
  • Developer Albert Einstein College of Medicine; Deciphera Pharmaceuticals
  • Class Amides; Antineoplastics; Fluorobenzenes; Pyrazoles; Pyridines; Quinolines; Small molecules; Urea compounds
  • Mechanism of Action Bcr-abl tyrosine kinase inhibitors; Fms-like tyrosine kinase 3 inhibitors; Lyn protein-tyrosine kinase inhibitors; Proto-oncogene protein c-hck inhibitors; TIE 2 receptor antagonists; TrkA receptor antagonists
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    No
  • New Molecular Entity Yes

Highest Development Phases

  • Discontinued Acute myeloid leukaemia; Breast cancer; Chronic myeloid leukaemia; Endometrial cancer; Ovarian cancer; Precursor cell lymphoblastic leukaemia-lymphoma; Solid tumours

Most Recent Events

  • 01 Nov 2022 Deciphera Pharmaceuticals completes a phase Ib/II trial for Solid tumours (Combination therapy, Late-stage disease, Metastatic disease, Second-line therapy or greater) in USA (PO) (NCT03717415)
  • 14 Apr 2022 Discontinued - Phase-I/II for Acute myeloid leukaemia in USA (PO) (Deciphera Pharmaceuticals' pipeline, April 2022)
  • 14 Apr 2022 Discontinued - Phase-I/II for Chronic myeloid leukaemia in Australia (PO) (Deciphera Pharmaceuticals' pipeline, April 2022)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top